Latest Operational Cash Flow News

Energy Action Limited reports a strong positive operating cash flow of $1.08 million in Q2 FY25, boosted by customer receipts and an R&D tax rebate, while advancing its AI-driven energy platform Utilibox to fuel future growth.

Energy Action Limited reported a positive net cash inflow from operating activities of $1.076 million for the December quarter, maintaining a solid cash position amid ongoing financing arrangements.

Airtasker Limited reported a robust second quarter with marketplaces revenue up 15.8%, driven by explosive growth in the UK and US, alongside positive free cash flow of $0.5 million. The company’s strategic media partnerships underpin its international expansion ambitions.

Hudson Investment Group signals potential corporate restructure as it explores sale and joint venture options for key Queensland and NSW properties.

Wrkr Ltd reports strong commercial progress and strategic hires in Q2 FY25, positioning itself for growth with key platform enhancements and pilot completions ahead of Payday Super implementation.

Jupiter Energy Limited reported a net operating cash inflow of $776,000 for the December 2024 quarter, maintaining a solid cash position despite heavy exploration expenditures.

Alpha HPA Limited has reached a major funding milestone with a $400 million senior debt package for its HPA First Project Stage 2, while experiencing accelerating demand from the semiconductor sector and advancing new product developments.

PYC Therapeutics reports substantial progress across all four of its drug development programs in Q4 2024, including key regulatory designations and clinical milestones that set the stage for pivotal trials in 2025.

AVADA Group Limited reports a positive cash flow for Q4 2024, supported by increased collections and operational consolidation, even as government funding shifts delay project starts.

Holista Colltech Limited reports a notable financial recovery in 4QFY24, underpinned by strong cash inflows and a rebound in its Food Ingredients division, alongside a leadership change aimed at steering future growth.

Actinogen Medical accelerates recruitment in its pivotal XanaMIA Alzheimer's trial while securing a strong cash position of $22.9 million, underpinning its late-stage development and commercial readiness.

Microba Life Sciences reported a robust Q2 FY25 with revenue more than doubling year-on-year, driven by strong sales of its MetaXplore microbiome test in Australia and promising early adoption in the UK.